Literature DB >> 29199921

Developing a community HCV service: project ITTREAT (integrated community-based test - stage - TREAT) service for people who inject drugs.

Ahmed Hashim1, Margaret O'Sullivan2, Hugh Williams3, Sumita Verma1.   

Abstract

Background and aims Majority of the individuals with hepatitis C virus (HCV) infection in England are people who inject drugs, a vulnerable and disenfranchised cohort with poor engagement with secondary care. Our aim is to describe our experiences in setting up a successful nurse led HCV service at a substance misuse service (SMS).
METHODS: We justify the need for a community HCV service and review the different community based models. Our experiences in engaging with stakeholders, obtaining funding, service set up, challenges faced and key recommendations are discussed. Finally, a summary of interim clinical outcomes is presented.
RESULTS: A successful community based "one-stop" nurse led HCV service was set up in Dec 2013 at a large SMS. It provides all aspects of care (blood borne virus screening, non-invasive assessment of hepatic fibrosis, Hepatology input, HCV treatment, peer mentor, social and psychiatrist support, and opiod substitution) at one site. Interim clinical data indicate high service uptake with HCV treatment outcomes comparable to secondary care.
CONCLUSIONS: The advent of direct acting antivirals provides a unique opportunity for HCV elimination in England by 2030. Our "one-stop" integrated and multidisciplinary community HCV model suggests that HCV care can be successfully delivered outside of a hospital setting and warrants national adoption.

Entities:  

Keywords:  CLD; HCV; PWID; community model; hepatitis C

Mesh:

Year:  2017        PMID: 29199921      PMCID: PMC6452958          DOI: 10.1017/S1463423617000731

Source DB:  PubMed          Journal:  Prim Health Care Res Dev        ISSN: 1463-4236            Impact factor:   1.458


  33 in total

1.  Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease--the LDQOL 1.0.

Authors:  I M Gralnek; R D Hays; A Kilbourne; H R Rosen; E B Keeffe; L Artinian; S Kim; D Lazarovici; D M Jensen; R W Busuttil; P Martin
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

2.  Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.

Authors:  W L Irving; S Smith; R Cater; S Pugh; K R Neal; C A C Coupland; S D Ryder; B J Thomson; M Pringle; M Bicknell; J Hippisley-Cox
Journal:  J Viral Hepat       Date:  2006-04       Impact factor: 3.728

3.  Prospective validation of the short form liver disease quality of life instrument.

Authors:  F Kanwal; B M R Spiegel; R D Hays; F Durazo; S B Han; S Saab; R Bolus; S J Kim; I M Gralnek
Journal:  Aliment Pharmacol Ther       Date:  2008-07-30       Impact factor: 8.171

4.  Limited uptake of hepatitis C treatment among injection drug users.

Authors:  Shruti H Mehta; Becky L Genberg; Jacquie Astemborski; Ravi Kavasery; Gregory D Kirk; David Vlahov; Steffanie A Strathdee; David L Thomas
Journal:  J Community Health       Date:  2008-06

5.  Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration.

Authors:  Herbert L Bonkovsky; Alan D Tice; Rockford G Yapp; Henry C Bodenheimer; Alexander Monto; Stephen J Rossi; Mark S Sulkowski
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

Review 6.  Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis.

Authors:  Jayant A Talwalkar; David M Kurtz; Scott J Schoenleber; Colin P West; Victor M Montori
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10       Impact factor: 11.382

7.  Adherence to hepatitis C treatment in recovering heroin users maintained on methadone.

Authors:  Diana L Sylvestre; Barry J Clements
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-09       Impact factor: 2.566

8.  Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C.

Authors:  K Jack; S Willott; J Manners; M A Varnam; B J Thomson
Journal:  Aliment Pharmacol Ther       Date:  2008-10-13       Impact factor: 8.171

9.  Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use.

Authors:  M Wilkinson; V Crawford; A Tippet; F Jolly; J Turton; E Sims; M Hekker; J Dalton; R Marley; G R Foster
Journal:  Aliment Pharmacol Ther       Date:  2008-08-26       Impact factor: 8.171

10.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998

View more
  3 in total

Review 1.  Hepatitis C models of care: approaches to elimination.

Authors:  Mia J Biondi; Jordan J Feld
Journal:  Can Liver J       Date:  2020-06-04

2.  Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder.

Authors:  Carlos Roncero; Pablo Ryan; Richard Littlewood; Juan Macías; Juan Ruiz; Pedro Seijo; Raúl Felipe Palma-Álvarez; Pablo Vega
Journal:  Hepat Med       Date:  2018-12-24

Review 3.  Viral hepatitis in 2021: The challenges remaining and how we should tackle them.

Authors:  Rebecca Dunn; Aaron Wetten; Stuart McPherson; Mhairi C Donnelly
Journal:  World J Gastroenterol       Date:  2022-01-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.